Information Provided By: 
Fly News Breaks for May 28, 2019
FPRX
May 28, 2019 | 16:30 EDT
Roth Capital analyst Tony Butler initiated Five Prime with a Neutral rating and a price target of $10. The analyst is positive on the company's "robust protein therapeutics platform" with additional upside potentially coming from its expected clinical updates from two early stage programs, also noting that the recent profitability efforts could also make it an "appealing M&A target". Butler warns however that "significant overhang" exists over Five Prime's lead Bemarituzumab program.
News For FPRX From the Last 2 Days
There are no results for your query FPRX
